MHM Magazine

S5 ALCHERA. Reg. No.: 33/2.2/0029. Each tablet contains 7,5 mg of zopiclone. S5 ATIVAN 1 mg. Reg. No.: D/2.6/126. Each tablet contains 1 mg of lorazepam. S5 ATIVAN 2,5 mg. Reg. No.: D/2.6/128. Each tablet contains 2,5 mg of lorazepam. S4 CARBILEV 25/250. Reg. No.: 30/5.4.1/0269. Each tablet contains 25 mg carbidopa and 250 mg of levodopa. S4 CARBILEV 25/100. Reg. No.: 30/5.4.1/0271. Each tablet contains 25 mg carbidopa and 100 mg of levodopa. S5 ESPIRIDE. Reg. No.: Y/2.5/386. Each capsule contains 50 mg of sulpiride. S5 NORMISON 10 mg. Reg. No.: L/2.2/125. Each soft gelatin capsule contains 10 mg of temazepam. S5 NORMISON 20 mg. Reg. No.: M/2.2/205. Each soft gelatin capsule contains 20 mg of temazepam. S5 TRANQIPAM - 1. Reg. No.: U/2.6/38. Each tablet contains 1 mg of lorazepam. S5 TRANQIPAM - 2,5. Reg. No.: U/2.6/39. Each tablet contains 2,5 mg of lorazepam. S5 TREPILINE 10. Reg. No.: J/1.2/219. Each tablet contains 10 mg of amitriptyline hydrochloride. S5 TREPILINE 25. Reg. No.: J/1.2/220. Each tablet contains 25 mg of amitriptyline hydrochloride. S5 VOLOXIN 50 mg . Reg. No.: 52/1.2/0952. Each extended release tablet contains desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. S5 V OLOXIN 100 mg. Reg. No.: 52/1.2/0953. Each extended release tablet contains desvenlafaxine succinate equivalent to 100 mg desvenlafaxine. S5 Vortioxetine 5 mg Aspen. Reg. No.: 54/1.2/0702. Each film-coated tablet contains 5 mg of vortioxetine. S5 Vortioxetine 10 mg Aspen. Reg. No.: 54/1.2/0703. Each film-coated tablet contains 10 mg of vortioxetine. S5 Vortioxetine 20 mg Aspen. Reg. No.: 54/1.2/0704. Each film-coated tablet contains 20 mg of vortioxetine. S5 ZOLNOXS 10 mg Tablets. Reg. No.: 36/2.2/0328. Each film-coated tablet contains 10 mg zolpidem tartrate. For full prescribing information refer to the professional information approved by the medicines regulatory authority (ALCHERA 10/2000; ATIVAN 1 mg and 2,5 mg 07/2012; CARBILEV 09/2022; ESPIRIDE 04/1998; NORMISON 12/1989; TRANQIPAM 02/1990; TREPILINE 07/2017; VOLOXIN 05/2020; Vortioxetine Aspen 11/2022; ZOLNOXS 10 mg Tablets 03/2022). Trademarks are owned by or licensed to the Aspen Group of companies. © 2024 Aspen Group of companies or its licensor. All rights reserved. Marketed by Pharmacare Limited t/a Aspen Pharmacare. Co. Reg. No.: 1898/000252/06. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-AMI-05-24-00001 06/2024. Indications: • For the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms ATIVAN is indicated only when the disorder has not responded to non medicine therapy, and is severe, disabling, or subjecting the individual to unacceptable distress. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic Indications: • For anxiety disturbances or anxiety states: (a) general anxiety disturbances (b) panic disturbances (c) phobic anxiety disturbances • For anxiety associated with and caused by organic disease • For adjustment disturbances with anxiety or stress reactions Indications: • Reactive depression, depression associated with psychoses of other origins. Prophylaxis and treatment of depressive psychoses • Schizophrenia, particularly with the symptoms of hallucination, autism, aggressiveness and with withdrawn-inhibited types of schizophrenia • Acute delirium, acute hallucinatory and confused states • Behaviour disorders in all age groups where abnormal aggressive symptoms are in the forefront • As an adjunct in the medical treatment of duodenal ulceration of psychosomatic origin • Vertigo • Anti-emesis TRANQUILLISER Indications: • For the short-term treatment of insomnia in adults A short-acting hypnotic, is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress Indication: • For the short-term treatment of insomnia in adults Indications: • For use as a hypnotic or night-time sedative in adults The prolonged administration of NORMISON is not recommended Premedication taken 30 to 60 minutes prior to surgical or other procedures Indication: • For the treatment of depression in patients 18 years and older Indication: • For the treatment of major depressive disorder (MDD) Indication: • For the treatment of major depressive disorder and to reduce the risk of relapse Indications: • Treatment of Parkinson’s disease and syndrome • To reduce “off” time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration, peak dose dyskynesias, akinesia, or similar evidence of short-duration motor disturbances SEDATIVE/HYPNOTIC ANTI-DEPRESSANT ANTI-PARKINSONISM